Soligenix Management

Management Kriterienprüfungen 2/4

Soligenix CEO ist Christopher Schaber , ernannt in Aug 2006, hat eine Amtszeit von 19.58 Jahren. Die jährliche Gesamtvergütung beträgt $832.63K , bestehend aus 64.9% Gehalt und 35.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.15% der Aktien des Unternehmens, im Wert von $17.84K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 11.3 Jahre bzw. 16.4 Jahre.

Wichtige Informationen

Christopher Schaber

Geschäftsführender

US$832.6k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	64.89%
Amtszeit als Geschäftsführer	19.6yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	11.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	16.4yrs

Jüngste Management Updates

Recent updates

Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely

Aug 20

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Christopher Schaber im Vergleich zu den Einnahmen von Soligenix verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2025	n/a	n/a	-US$11m
Jun 30 2025	n/a	n/a	-US$10m
Mar 31 2025	n/a	n/a	-US$10m
Dec 31 2024	US$833k	US$540k	-US$8m
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m

Vergütung im Vergleich zum Markt: ChristopherDie Gesamtvergütung ($USD832.63K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD572.27K).

Entschädigung vs. Einkommen: ChristopherDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Christopher Schaber (59 yo)

19.6yrs

Amtszeit

US$832,626

Vergütung

Dr. Christopher J. Schaber, Ph D., is Trustee of BioNJ Inc. Dr. Schaber was Trustee of BioNJ Inc. until February 2019. Dr. Schaber has been the President and Chief Executive Officer at Soligenix, Inc. sinc...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Schaber	Chairman of the Board of Directors	19.6yrs	US$832.63k	0.15% $ 17.8k
Jonathan Guarino	Senior VP	6.5yrs	US$399.18k	0.00046% $ 53.4
Oreola Donini	Senior VP & Chief Scientific Officer	11.3yrs	US$432.11k	0% $ 0
Richard Straube	Consultant	12.2yrs	US$268.68k	0.00034% $ 39.4
Adam Rumage	Senior VP of Project Management & Regulatory Affairs	less than a year	keine Daten	keine Daten

11.3yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von SNGX ist erfahren und erfahren (durchschnittliche Amtszeit von 11.3 Jahren).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Schaber	Chairman of the Board of Directors	19.6yrs	US$832.63k	0.15% $ 17.8k
Jerome Zeldis	Independent Director	14.8yrs	US$80.00k	0.00095% $ 110.2
Gregory Lapointe	Independent Director	17yrs	US$85.00k	0.00031% $ 36.0
Robert Rubin	Independent Director	16.4yrs	US$87.50k	0.00019% $ 22.0
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	keine Daten	keine Daten
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	keine Daten	keine Daten
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	keine Daten	keine Daten
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	keine Daten	keine Daten
Brian Poligone	Chair of Cutaneous T-Cell Lymphoma Medical Advisory Board	less than a year	keine Daten	keine Daten

16.4yrs

Durchschnittliche Betriebszugehörigkeit

70.5yo

Durchschnittliches Alter

Erfahrener Vorstand: SNGXDie Vorstandsmitglieder sind sehr erfahren ( 16.4 ).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/06 10:24
Aktienkurs zum Tagesende	2026/03/06 00:00
Gewinne	2025/09/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, mit dem dieser Bericht erstellt wurde, sind auf unserer Github-Seite verfügbar. Außerdem bieten wir Anleitungen zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Soligenix, Inc. wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
James Molloy	Alliance Global Partners
Andrew D'Silva	B. Riley Securities, Inc.
Keith Markey	Griffin Securities

Soligenix Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Recent updates

Soligenix, Inc. Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for Sgx945 for the Treatment of Behcet's Disease

New major risk - Revenue and earnings growth

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $3.45 million.

Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)

Soligenix Inc. Announces Audio Press Release on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™? for the Treatment of Cutaneous T-Cell Lymphoma

New major risk - Financial position

Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc. has completed a Follow-on Equity Offering in the amount of $7.500006 million.

New major risk - Market cap size

Soligenix, Inc. has filed a Follow-on Equity Offering in the amount of $7.999998 million.

Soligenix, Inc. Announces Publication Recommending Long-Term High Temperature Stability of Protein Subunit Vaccines forbola and Related Viruses

Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely

Soligenix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for its Common Stock

Soligenix Inc. Announces Audio Press Release on Promising First-Line Therapy for Rare Skin Cancer

New major risk - Share price stability

Soligenix, Inc. Completes its Phase 2a Proof of Concept Study Evaluating SGX945 (Dusquetide) in Treatment of Behcet's Disease and Achieves Study Objective of Demonstrating Biological Efficacy

Soligenix, Inc. Announces Synthetic Hypericin Successfully Manufactured At Sterling Pharma Solutions

Soligenix, Inc. Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials

First quarter 2025 earnings released: US$1.06 loss per share (vs US$2.91 loss in 1Q 2024)

Soligenix, Inc., Annual General Meeting, Jun 20, 2025

Soligenix, Inc. Announces Interim Results from the Ongoing Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

No longer forecast to breakeven

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte

Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma